Cavatak at half a bill wasn’t designed to be the same functioning bio as Keytruda it was a combo therapy drug - also Cavatak was primarily melanoma
From what my understanding is IMUs IP is combo therapy but also competing I.e in recent phase 2 trial where access to the major drugs aren’t so readily available) and a variety of cancers so I would think it would be worth more perhaps down the line ?Naturally data has to come first and also depends on the market share and $ value of the competitors
Could be wrong on this just thinking out loud per se
IMU Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
(20min delay)
